Company Active LTD

Company profile

Jiva.Ai Limited

Jiva.ai - Low Code AI Platform - Next Gen Multimodal AI - Create, Test, Validate Deploy

Jiva Auto ML/AI Multimodal Platform allows you to create multiple AI models using differing AI techniques (CNN, Bayesian, ANN, Multimodal, RFT) which can then be tested and deployed.

CRN
11810672
Founded
2019
Age
7

Overview

Legal name
JIVA.AI LIMITED
Region
Wales
Registered address
TRAMSHED TECH
PENDYRIS STREET
CARDIFF
WALES
CF11 6BH
Insolvency history
No

Latest accounts

Financial period: 1 Jan 2024 to 31 Dec 2024

FILLETEDACCOUNTS
Turnover
Unknown
Profit / Loss
Unknown
Employees
17

Company events

Reference milestones and recent Companies House filing stream events.

7 events
30 Sep
2027

Accounts due

Accounts Due

Next accounts due date

23 Feb
2027

Confirmation statement due

Confirmation Due

Next confirmation statement due date

09 Feb
2026

Confirmation statement filed

Confirmation

Last confirmation statement made up date

31 Dec
2025

Accounts filed

Accounts

Last accounts made up date

15 Nov
2024

Capital Allotment Shares

Capital

SH01 | Transaction MzQ0MzU4MzA2MGFkaXF6a2N4

Published 15 Nov 2024 03:11

30 Oct
2024

Capital Allotment Shares

Capital

SH01 | Transaction MzQ0MTQyNjE1NmFkaXF6a2N4

Published 30 Oct 2024 10:25

06 Feb
2019

Incorporated

Inception

Company registered at Companies House

Public funding

5 awards
First funded
2020
Funded years
2020, 2023, 2024, 2025
Age at first award
1 years

Projects

2025 Investment Accelerator

GM Advanced Diagnostics Accelerator (ADA) - Extension

1 Apr 2025 to 31 Mar 2026

Awarded
£73,988
Total cost £105,694

The understanding of disease mechanisms is advancing rapidly, leading to innovations which enable earlier and more accurate detection, diagnosis and prognostication, including ruling-out disease in those who can be safely reassured. This gives opportunities for better population health and targeted care pathways bespoke to individuals. However, there rema...

2024 Collaborative R&D

Developing tools for pre-market evaluation and post-market surveillance of Medical Imaging AI

1 Jan 2024 to 31 Dec 2024

Awarded
£45,662
Total cost £65,231

AI tools have shown promise in being able to analyse medical imaging and aid healthcare professionals with their image interpretation speed and accuracy. However, the uptake of these algorithms by healthcare organisations has been slow for several reasons including: ● Lack of independent clinical testing about the accuracy of the algorithms. ● Lack of tra...

2023 Collaborative R&D Lead participant

Joint collaboration to develop a predictive method for preventive medicine in asthma care

1 Nov 2023 to 31 Oct 2025

Awarded
£299,340
Total cost £427,629

Asthma management is a significant burden on healthcare systems globally. Billions of dollars are spent on management of the disease when it is too late, with the patient requiring treatment in secondary care. The development of remote technology has improved dramatically in recent years, generating large amounts of data that could aid in predicting the o...

2023 Investment Accelerator

GM Advanced Diagnostics Accelerator

1 Apr 2023 to 31 Mar 2025

Awarded
£163,990
Total cost £234,272

no public description

2020 Collaborative R&D

Integrated Diagnostics for Early Diagnosis of Liver Disease [ID-LIVER]

1 Sep 2020 to 31 Aug 2023

Awarded
£127,603
Total cost £182,290

Liver disease is an epidemic with up to four in ten people having health problems from their liver not working properly. A proportion of these patients develop scarring that is most commonly picked up late but which can progress without stopping to complete liver failure. It is one of the UK's largest health challenges for which we do not have answers. At...

Product types

Collaborative R&D Investment Accelerator